Kisand K E, Karvonen A L, Vuoristo M, Färkkilä M, Lehtola J, Inkovaara J, Kisand K V, Miettinen T, Krohn K, Uibo R
Department of Immunology, University of Tartu, Estonia.
J Mol Med (Berl). 1996 May;74(5):269-72. doi: 10.1007/BF00196579.
A two-year randomized, double-blind, placebo-controlled clinical trial used paired serum samples from 122 patients with primary biliary cirrhosis to compare the effect of ursodeoxycholic acid and colchicine on their immune parameters. IgG antibodies to pyruvate dehydrogenase, the major autoantigen in primary biliary cirrhosis, were determined by enzyme-linked immunosorbent assay and immunoblot; enzyme inhibition assay against pyruvate dehydrogenase was used to test the changes of the functional reactivity of the serum autoantibodies. Treatment with ursodeoxycholic acid decreased both the level of IgG antibodies to pyruvate dehydrogenase (P < 0.01) and the inihibitory titer of the sera for pyruvate dehydrogenase (P < 0.01). Treatment with colchicine or placebo showed no statistically significant changes in either the antibody levels or the inhibitory titers. Ursodeoxycholic acid thus alters the immune parameters of patients with primary biliary cirrhosis. The mechanism of these changes needs further investigation.
一项为期两年的随机、双盲、安慰剂对照临床试验，使用了122例原发性胆汁性肝硬化患者的配对血清样本，以比较熊去氧胆酸和秋水仙碱对其免疫参数的影响。通过酶联免疫吸附测定和免疫印迹法测定原发性胆汁性肝硬化主要自身抗原丙酮酸脱氢酶的IgG抗体；采用针对丙酮酸脱氢酶的酶抑制试验来检测血清自身抗体功能反应性的变化。熊去氧胆酸治疗可降低丙酮酸脱氢酶IgG抗体水平（P<0.01）以及血清对丙酮酸脱氢酶的抑制效价（P<0.01）。秋水仙碱或安慰剂治疗在抗体水平或抑制效价方面均未显示出统计学上的显著变化。因此，熊去氧胆酸可改变原发性胆汁性肝硬化患者的免疫参数。这些变化的机制需要进一步研究。
